Trial
NCT02587962
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Medivir
Collaborators
Merck Sharp & Dohme LLC
Condition
Solid Tumors
Intervention
Birinapant
Why stopped
Based on a futility analysis, the data monitoring committee recommended to stop enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-14